Scancell (LON:SCLP) Trading Up 7% Following Insider Buying Activity

Scancell Holdings plc (LON:SCLP) rose 7% during trading on Wednesday after an insider bought additional shares in the company. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares changed hands during mid-day trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle purchased 44,944 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were acquired at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,429.48).

Scancell Price Performance

The stock’s 50 day moving average price is GBX 9.38 and its two-hundred day moving average price is GBX 10.21. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The firm has a market capitalization of £102.54 million, a price-to-earnings ratio of -15.18 and a beta of 0.35.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.